Understanding Myelodysplastic Syndromes (MDS): Symptoms, Diagnosis, Genetics, and Treatment

By

What Are Myelodysplastic Syndromes (MDS)?

Myelodysplastic syndromes (MDS), also called myelodysplastic neoplasms, are a group of disorders in which the bone marrow does not produce enough healthy, mature blood cells. Instead, blood-forming cells may develop abnormally, fail to mature properly, or die prematurely.

Because bone marrow is responsible for producing red blood cells, white blood cells, and platelets, MDS can result in shortages of one or more of these important types of blood cells.

MDS varies considerably from person to person. Some forms progress slowly and may require little or no immediate treatment, while others are more aggressive and have a greater risk of progressing to acute myeloid leukemia (AML).

Bone Marrow Failure

In MDS, abnormal blood-forming cells can interfere with the bone marrow's ability to produce healthy blood cells. Although the bone marrow may contain many developing cells, relatively few mature, functional cells may reach the bloodstream. This process is known as ineffective hematopoiesis.

As a result, patients can develop low blood counts, known collectively as cytopenias.

Low Blood Counts

MDS may cause a shortage of:

  • Red blood cells, resulting in anemia.
  • White blood cells, particularly neutrophils, increasing susceptibility to infection.
  • Platelets, increasing the risk of bruising and bleeding.

Some people have only one type of low blood count, while others have two or all three.

Risk of Acute Myeloid Leukemia

MDS is considered a type of blood cancer and, in some patients, can progress to acute myeloid leukemia (AML). The likelihood of progression varies substantially according to the type of MDS and its genetic, chromosomal, and clinical characteristics.

Because of this risk, determining an individual's MDS subtype and risk category is an important part of diagnosis and treatment planning.

Common Symptoms of MDS

MDS does not always cause noticeable symptoms in its early stages. Some people first learn that they have abnormal blood counts after a routine complete blood count (CBC).

When symptoms develop, they often depend on which blood cell types are affected.

Anemia — Low Red Blood Cells

Red blood cells transport oxygen throughout the body. When their numbers are too low, symptoms may include:

  • Persistent or severe tiredness
  • Weakness
  • Shortness of breath
  • Dizziness
  • Pale skin
  • Reduced ability to exercise or perform normal activities

Neutropenia — Low Neutrophils

Neutrophils are white blood cells that play an important role in fighting bacterial and fungal infections. Low neutrophil levels may lead to:

  • Frequent infections
  • Infections that are unusually severe or difficult to treat
  • Fever
  • Recurrent respiratory or other infections

A fever in someone with severe neutropenia can require urgent medical assessment.

Thrombocytopenia — Low Platelets

Platelets help the blood clot. When platelet levels are low, symptoms can include:

  • Easy or unexplained bruising
  • Prolonged bleeding
  • Frequent nosebleeds
  • Bleeding gums
  • Tiny red or purple spots under the skin, known as petechiae

Causes and Risk Factors

For many patients, there is no single identifiable cause of MDS. However, several factors are associated with an increased risk.

Age

MDS occurs most commonly in older adults, with the majority of patients diagnosed after age 60.

Previous Cancer Treatment

Some people develop MDS after receiving certain types of chemotherapy or radiation therapy for another cancer. This is referred to as therapy-related MDS.

Chemical and Environmental Exposure

Long-term or significant exposure to certain substances has also been associated with an increased risk of MDS. Examples include:

  • Tobacco smoke
  • Benzene
  • Certain industrial chemicals or solvents

Having one or more risk factors does not mean that a person will develop MDS, and many patients have no identifiable environmental or treatment-related cause.

How Is MDS Diagnosed?

Diagnosis usually begins when a blood test reveals persistently abnormal blood cell counts.

A complete blood count (CBC) measures the numbers of red blood cells, white blood cells, and platelets. Examination of a peripheral blood smear can also provide information about the size, shape, and appearance of the blood cells.

If MDS is suspected, doctors typically perform a bone marrow aspiration and biopsy. These procedures allow specialists to examine bone marrow cells, determine whether abnormal or immature cells are present, measure the percentage of blast cells, and perform genetic and chromosomal testing.

Other conditions that can produce similar blood abnormalities generally need to be considered and excluded as part of the diagnostic process.

Genetic and Chromosomal Testing in MDS

Genetic testing has become increasingly important in MDS. The chromosomal and molecular abnormalities found in abnormal bone marrow cells can help doctors classify the disease, estimate its prognosis, and, in some circumstances, select treatment.

Conventional Cytogenetics — Karyotyping

Karyotyping examines chromosomes from dividing bone marrow cells. It can identify relatively large chromosomal abnormalities, including:

  • Missing chromosomes
  • Extra chromosomes
  • Deletions of part of a chromosome
  • Duplications
  • Rearrangements between chromosomes

Cytogenetic findings are an important component of MDS diagnosis and risk assessment.

Fluorescence In Situ Hybridization (FISH)

Fluorescence in situ hybridization (FISH) uses fluorescently labeled DNA probes designed to detect particular chromosomal abnormalities.

Unlike conventional karyotyping, FISH does not require cells to be actively dividing. However, it generally looks only for the specific abnormalities targeted by the probes being used, so it does not replace all other forms of genetic testing.

Next-Generation Sequencing (NGS)

Next-generation sequencing (NGS) can analyze many genes simultaneously to identify acquired, or somatic, mutations in abnormal blood-forming cells.

Genes commonly mutated in MDS include:

  • SF3B1
  • TP53
  • TET2
  • ASXL1
  • DNMT3A
  • RUNX1

These mutations do not all have the same meaning. Their significance depends on the particular gene, mutation, accompanying chromosomal abnormalities, blood counts, blast percentage, and other clinical factors.

Important Chromosomal and Molecular Abnormalities

Deletion 5q — del(5q)

A deletion involving part of the long arm of chromosome 5 is known as del(5q).

MDS with an isolated del(5q), or with certain limited additional abnormalities, can have distinctive clinical characteristics and may respond particularly well to lenalidomide, especially when anemia and transfusion dependence are major problems.

The presence of additional high-risk abnormalities, including certain TP53 mutations, can substantially alter the prognosis and treatment approach.

Monosomy 7 and del(7q)

Monosomy 7 (-7) means that one copy of chromosome 7 is missing. del(7q) means that part of the long arm of chromosome 7 has been deleted.

These abnormalities are often associated with higher-risk disease, although their significance must be interpreted together with the patient's other clinical and molecular findings.

Trisomy 8

Trisomy 8 (+8) means that an abnormal cell contains an additional copy of chromosome 8. It is one of the recurrent cytogenetic abnormalities observed in MDS.

Its prognostic significance depends on the broader clinical and genetic context.

Complex Karyotype

A complex karyotype refers to the presence of multiple chromosomal abnormalities within the abnormal cell population. Definitions can vary according to the classification or risk system being used.

Complex chromosomal changes are generally associated with higher-risk disease. They are particularly important when associated with abnormalities involving TP53, which can indicate biologically aggressive disease.

The Role of Genetics in Prognosis and Risk Scoring

MDS is not a single disease, which means two patients with MDS may have very different expected disease courses.

Modern risk-assessment systems incorporate several types of information to estimate prognosis.

One important system is the Molecular International Prognostic Scoring System (IPSS-M). It incorporates molecular mutation data together with clinical and hematologic information to provide a more individualized assessment of disease risk.

Risk assessment may consider factors such as:

  • Hemoglobin level
  • Platelet count
  • Neutrophil count
  • Bone marrow blast percentage
  • Chromosomal abnormalities
  • Specific gene mutations

These findings help estimate the likelihood of disease progression and can contribute to treatment planning. Risk scores are useful clinical tools, but they are not precise predictions of what will happen to an individual patient.

Treatment and Management of MDS

Treatment varies considerably depending on the patient's MDS subtype, risk category, symptoms, age, overall health, genetic findings, and personal treatment goals.

Observation

Some patients with lower-risk MDS and relatively stable blood counts may not require immediate treatment. Their condition may instead be monitored through regular blood tests and clinical evaluations.

Supportive Treatment

Supportive care aims to manage the consequences of low blood counts and may include:

  • Red blood cell transfusions
  • Platelet transfusions
  • Antibiotics when infections occur
  • Growth factors or other medications to stimulate blood-cell production in selected patients
  • Treatment of iron overload when repeated transfusions make this necessary

Disease-Directed Medicines

Several medications may be used depending on the specific type and risk level of MDS. These can include hypomethylating agents such as azacitidine or decitabine, as well as treatments directed toward particular clinical or molecular features.

For example, lenalidomide has an important role in selected patients with lower-risk MDS with del(5q).

Luspatercept may be used to treat anemia in selected patients with lower-risk MDS, particularly in certain settings involving ring sideroblasts or SF3B1-related disease. Treatment eligibility depends on the patient's full clinical situation rather than the presence of an SF3B1 mutation alone.

Stem Cell Transplantation

An allogeneic hematopoietic stem cell transplant replaces abnormal blood-forming stem cells with healthy donor stem cells.

It is currently the principal treatment with the potential to cure MDS, but it also carries significant risks. Doctors therefore consider factors such as disease risk, age, overall health, donor availability, genetic findings, and the patient's preferences when deciding whether transplantation is appropriate.

Why Genetic Testing Matters

Genetic and chromosomal testing has transformed the way MDS is understood and managed. Rather than relying solely on blood counts and the appearance of bone marrow cells, specialists can increasingly examine the biological characteristics driving an individual's disease.

These results can help with diagnosis and classification, distinguish different forms of MDS, provide information about prognosis and the risk of progression to AML, and sometimes identify patients who are more likely to benefit from particular treatments.

Genetic results can also influence decisions about whether a patient should continue with observation and supportive care or be considered for more intensive therapy, clinical trials, or stem cell transplantation.

Conclusion

Myelodysplastic syndromes are a diverse group of blood cancers characterized by ineffective production of healthy blood cells. Their effects can range from mild, slowly developing anemia to severe bone marrow failure and progression to acute myeloid leukemia.

Advances in cytogenetic testing, FISH, and next-generation sequencing have greatly improved doctors' ability to classify MDS and understand an individual patient's disease. Findings such as del(5q), chromosome 7 abnormalities, trisomy 8, complex karyotypes, and mutations involving genes such as SF3B1 and TP53 can provide valuable information for risk assessment and treatment planning.

Because MDS varies so widely between individuals, genetic findings should always be interpreted alongside blood counts, bone marrow findings, symptoms, age, overall health, and other clinical factors. A hematologist or hematologist-oncologist can explain what a patient's particular results mean and discuss the most appropriate monitoring and treatment options.

This article is intended for general educational purposes and should not replace individualized medical advice, diagnosis, or treatment from a qualified healthcare professional.

References:

Myelodysplastic syndromes - causes, symptoms, diagnosis, treatment, pathology
https://www.youtube.com/watch?v=fT_NTuZSbkQ

Acute Intermittent Porphyria (AIP), Hematin, Warfarin, Viral Infections, and Petechiae: A Comprehensive Clinical Overview
https://swaresearch.blogspot.com/2025/11/acute-intermittent-porphyria-aip.html

Understanding Coagulopathy: From Liver Disease to Genetic Disorders Involving Platelets and Clotting Factors
https://swaresearch.blogspot.com/2025/05/understanding-coagulopathy-from-liver.html

Myelodysplastic syndromes:
https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/symptoms-causes/syc-20366977

Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version
https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq

Myelodysplastic Syndromes (MDS)
https://www.msdmanuals.com/professional/oncology/leukemias/myelodysplastic-syndromes-mds

Genetic Testing in #MDS: What Patients Need to Know
https://www.youtube.com/watch?v=JA3P6yU9TXY&t=7s

Genetics of Myelodysplastic Syndromes
https://pmc.ncbi.nlm.nih.gov/articles/PMC8304604/

Tests for Myelodysplastic Syndromes (MDS)
https://www.cancer.org/cancer/types/myelodysplastic-syndrome/detection-diagnosis-staging/how-diagnosed.html

Genetic markers: TET2 citation for rs10010325
https://pubmed.ncbi.nlm.nih.gov/33311554/
15 citations for rs9790517
https://www.ncbi.nlm.nih.gov/snp/rs9790517#publications

© 2025-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9 


Comments

Post a Comment

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

By
Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

By
Acute flaccid myelitis (AFM) is a rare but serious neurological disorder that primarily affects children and results in sudden weakness or paralysis in the limbs. Often referred to as a “polio-like” illness, AFM has drawn growing attention over the past decade due to its similarities with poliomyelitis and its seasonal spikes in reported cases. While AFM remains uncommon, its potential severity—and the uncertainty surrounding its causes—make it an important condition for clinicians, parents, and public health officials to understand. What Is Acute Flaccid Myelitis? AFM is a condition that affects the gray matter of the spinal cord , where it damages motor neurons responsible for muscle movement. This leads to acute, flaccid paralysis , meaning muscles become limp and weak, often without warning. The condition can progress rapidly, and in some cases, the weakness can become long-lasting or even permanent. Although its symptoms resemble those of poliovirus infection, AFM is not cau...
Read more

Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

By
Image
Introduction: White Brain Matter, VLCFAs, and X-ALD X-linked Adrenoleukodystrophy (X-ALD) is a rare inherited metabolic disorder and a major cause of progressive neurodegeneration in children—sometimes referred to as “childhood dementia.” Across related conditions, prevalence can range from approximately 1 in 2,000 to 1 in 500,000 newborns. Among its forms, childhood cerebral X-ALD is the most severe, marked by rapid inflammatory demyelination in the brain and often fatal outcomes if not treated early. At the core of X-ALD is a disruption in the metabolism of Very Long-Chain Fatty Acids (VLCFAs). Normally, these fatty acids are broken down in peroxisomes—specialized structures within cells that help maintain metabolic balance. In X-ALD, a mutation in the ABCD1 gene impairs this function, causing VLCFAs to accumulate, particularly in the white matter of the brain, spinal cord, and adrenal glands. This accumulation leads to demyelination, adrenal insufficiency (Addison’s disease), an...
Read more

Polio and Post-Polio Syndrome (PPS): Summary and Key Insights

By
Image
Abstract Post-Polio Syndrome (PPS) develops in some survivors of paralytic poliomyelitis decades after recovery and is characterized by new or progressive muscle weakness, fatigue, pain, and reduced endurance. The prevailing pathophysiological model attributes PPS primarily to the gradual deterioration of enlarged motor units formed through compensatory axonal sprouting after the initial poliovirus (PV) infection. Although immune dysregulation and chronic systemic inflammation have been investigated as potential mechanisms, current evidence does not support classifying PPS as a primarily dysimmune or chronically inflammatory disorder. Nevertheless, the possible persistence of poliovirus-derived material and its biological significance remain subjects of investigation. Evidence for viral persistence has been reported in subsets of patients with PPS. In one study of 47 patients, elevated anti-poliovirus IgM antibodies were detected in some individuals, with titers reaching 1:250 compared...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By
Image
My Journey Toward Understanding Spinal Muscular Atrophy (SMA) Today, I better understand why Spinal Muscular Atrophy (SMA) received so little attention, particularly during the 1950s. This complex and debilitating genetic disorder was poorly understood, and patients’ symptoms could easily be minimized, misinterpreted, or dismissed. Even today, SMA can present significant diagnostic challenges, particularly in adults with complex medical histories. In my own experience, comprehensive investigations into the underlying cause of progressive muscle weakness were not always pursued. A Long and Complicated Diagnostic Journey In 2008, while being investigated for permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II .  I underwent surgery in 2009, but unfortunately, my symptoms did not improve. In 2010, a DNA test identified a genetic marker involving the ACTN3 gene . Further information about ACTN3 and its possible relation...
Read more

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By
Image
Important update: My experiences have now been formally verified following several years of dismissal. Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations https://link.springer.com/article/10.1186/s12985-025-03032-x  ----------------------------------------- Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially pres...
Read more

Cytokine Storm, Mast Cell Activation Syndrome (MCAS), Endothelial Dysfunction and microclots/thrombosis?

By
Update: New Research Builds on Previous Findings Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=040925&adv= Conclusions: This recent cohort study builds upon earlier work by identifying COVID-related cytokine storm (COVID-CS) through common inflammation markers and comparing it with two other cytokine storm (CS) conditions: malignancy-associated hemophagocytic lymphohistiocytosis (MN-HLH) and CAR-T–associated cytokine release syndrome (CAR-T CRS) . Among the three groups, patients treated with CAR-T therapy showed the highest survival rates , in contrast to those with COVID-CS and MN-HLH. Interestingly, the study found that CAR-T CRS and COVID-CS share similar cytokine activation pathways , suggesting a comparable immune response mechanism. In c...
Read more

The Impact of Acids on Muscular and Vascular Systems: Potential Negative Outcomes

By
This is ongoing research, and updates will be included as soon as they become available. A kidney transplant recipient with acute SARS-CoV-2 infection developed rhabdomyolysis and severe acute kidney injury (AKI) . A muscle biopsy confirmed findings consistent with immune-mediated necrotising myositis. Acid exposure and acid–base imbalances may profoundly affect the muscular and vascular systems. Strong acids from external sources, such as industrial chemicals, can cause corrosive tissue damage, while internal disturbances associated with metabolic disorders may disrupt cellular function and contribute to systemic complications. This article explores the potential effects of external acid exposure and internal acid–base disturbances on muscular and vascular health, including those associated with metabolic or genetic conditions. Because susceptibility to ME/CFS and complications following COVID-19 varies among individuals, further research may help determine whether genetic variant...
Read more

Impact of Penicillium on Muscle and Lung Function: What Healthcare Professionals Should Know

By
Image
Introduction While symbiotic relationships between viruses and bacteria have been documented, the possibility of a symbiosis between COVID-19 (SARS-CoV-2) and common fungal genera such as Penicillium , Aspergillus , and Trichoderma remains unexplored. This gap in research presents a potential area of interest for understanding novel microbial interactions and their implications for human health. Symbiosis Between Viruses and Bacteria – A Fascinating Partnership in the Microbial World https://swaresearch.blogspot.com/2025/07/symbiosis-between-viruses-and-bacteria.html When viruses, bacteria, or fungi—such as Penicillium —enter a host, they can trigger a range of immune responses and physiological disruptions.  Penicillium molds do not directly produce autoantibodies. However, exposure to Penicillium mold and its mycotoxins can trigger an immune response that may lead to the production of IgG antibodies , including those that could be reactive against the body's own tissues ,...
Read more